|
Volumn 62, Issue 5, 2008, Pages 837-840
|
Interpreting and applying the EUFEST results using number needed to treat: Antipsychotic effectiveness in first-episode schizophrenia
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMISULPRIDE;
ANTIDEPRESSANT AGENT;
BENZODIAZEPINE DERIVATIVE;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
HALOPERIDOL;
MOOD STABILIZER;
NEUROLEPTIC AGENT;
OLANZAPINE;
PERPHENAZINE;
QUETIAPINE;
RISPERIDONE;
ZIPRASIDONE;
AKATHISIA;
CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA;
CLINICAL GLOBAL IMPRESSION SCALE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
HUMAN;
HYPERPROLACTINEMIA;
LOW DRUG DOSE;
MANCHESTER SHORT ASSESSMENT OF QUALITY OF LIFE SCALE;
PARKINSONISM;
POSITIVE AND NEGATIVE SYNDROME SCALE;
PRIORITY JOURNAL;
RATING SCALE;
SCHIZOPHRENIA;
SHORT SURVEY;
SIDE EFFECT;
SYMPTOMATOLOGY;
TREATMENT OUTCOME;
UNSPECIFIED SIDE EFFECT;
WEIGHT GAIN;
ADULT;
ANTIPSYCHOTIC AGENTS;
FEMALE;
HALOPERIDOL;
HUMANS;
MALE;
PATIENT COMPLIANCE;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SCHIZOPHRENIA;
TREATMENT OUTCOME;
|
EID: 42149146835
PISSN: 13685031
EISSN: 17421241
Source Type: Journal
DOI: 10.1111/j.1742-1241.2008.01758.x Document Type: Short Survey |
Times cited : (9)
|
References (7)
|